Funding for this research was provided by:
Pharmaceutical Management Agency of New Zealand
Text and Data Mining valid from 2020-04-15
Received: 18 May 2019
Accepted: 13 February 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: The study complied with the Declaration of Helsinki. Ethics approval for the study was provided by the University of Auckland Human Participants Ethics Committee (Ref. 017777). As this was an anonymous survey study, signed written consent could not be obtained. Rather, the participant information sheet stated that “By completing the anonymous survey, you are agreeing to participation in this study”.
: Not applicable.
: Nicola Dalbeth declares that she has received speaking fees from Pfizer, Horizon, Janssen, and AbbVie, consulting fees from Horizon, Hengrui, Arthrosi, Dyve BioSciences, and Kowa, and research funding from Amgen and AstraZeneca, and is currently principal investigator on a clinical trial of intensive urate-lowering therapy (funded by the Health Research Council of New Zealand). She also declares that within the past 5 years she has been principal investigator on a clinical trial of febuxostat in early gout and has received consulting or speaking fees from Takeda, Menarini, and Teijin. The other authors have no conflicts of interest to disclose.